Username:

Password:
GO

TARGET TO PATIENT 2024
Organised by the European Bioinformatics Institute (EMBL | EBI) with support from the SMR
Monday 29th - Tuesday 30th April 2024
The Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1RQ
Early bird registration is now open

OVERVIEW

Target to Patient conference is returning to Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridge, UK OR online via our dedicated Target to Patient conference web portal. Advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML and digital health are transforming our understanding of disease leading to an explosion of new opportunities in drug discovery. Join us to hear scientific leaders explore how these advances are being used to identify new drug targets and create opportunities for improved pre-clinical work and clinical trials design.

Additional info: Both audiences, face-to-face and virtual, will experience presentations from our esteemed panel of speakers, participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials.

This meeting will focus on ground-breaking advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML, digital health, and how they could radically increase the discovery of disease relevant biological targets and the development of new drugs. Abstracts for consideration for poster presentations can be submitted during registration.

Target audience: Participants from industry, academia and government interested in challenging the existing approaches to target selection and translation are encouraged to attend and set the agenda for the next era of drug discovery.

Keynotes:

Hear the latest from industry leaders on how advances in #genomics for target choice, #invitro technologies, novel modalities, #AIML, and #digitalhealth can radically increase the discovery of disease relevant biological targets and the development of new drugs.

Early bird registration is now open... Click here

OVERVIEW